<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="review-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bmjour</journal-id><journal-title-group><journal-title xml:lang="ru">Байкальский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Baikal Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-0715</issn><publisher><publisher-name>Irkutsk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.57256/2949-0715-2024-3-71-82</article-id><article-id custom-type="elpub" pub-id-type="custom">bmjour-238</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Лекции для студентов, ординаторов и аспирантов</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Lectures for students, residents and postgraduates</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ ТКАНЕВЫХ АНГИОТЕНЗИНОВ НА ЭЛЕМЕНТЫ КАРДИОВАСКУЛЯРНОЙ СИСТЕМЫ (ЛЕКЦИЯ 2)</article-title><trans-title-group xml:lang="en"><trans-title>THE INFLUENCE OF TISSUE ANGIOTENSINS ON ELEMENTS OF THE CARDIOVASCULAR SYSTEM (LECTURE 2)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4217-0617</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуцол</surname><given-names>Людмила Олеговна</given-names></name><name name-style="western" xml:lang="en"><surname>Gutsol</surname><given-names>Liudmila O</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.б.н., доцент, доцент кафедры патологической физиологии и клинической лабораторной диагностики ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1</p></bio><bio xml:lang="en"><p>Cand. Sci. (Вiol.), associate professor, associate professor of Department of Pathological Physiology and Clinical Laboratory Diagnostics, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1. </p></bio><email xlink:type="simple">gutzol@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7504-4938</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Егорова</surname><given-names>Ирина Эдуардовна</given-names></name><name name-style="western" xml:lang="en"><surname>Egorova</surname><given-names>Irina E</given-names></name></name-alternatives><bio xml:lang="en"><p>Cand. Sci. (Med.), associate professor, associate professor of the Department of Chemistry and Biochemistry, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1.<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>09</month><year>2024</year></pub-date><volume>3</volume><issue>3</issue><fpage>71</fpage><lpage>82</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гуцол Л.О., Егорова И.Э., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Гуцол Л.О., Егорова И.Э.</copyright-holder><copyright-holder xml:lang="en">Gutsol L.O., Egorova I.E.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bmjour.ru/jour/article/view/238">https://www.bmjour.ru/jour/article/view/238</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Одной из основных причин смертности по данным Всемирной организации здравоохранения являются кардиоваскулярные заболевания. Хорошо известно, что нарушение регуляции и/или сверхэкспрессия элементов ренин-ангиотензиновой системы приводит к множеству негативных сосудистых эффектов, способствуя тем самым развитию сердечно-сосудистых заболеваний и патологических процессов, включая артериальную гипертензию, аневризмы, застойную сердечную недостаточность, инсульт, ишемическую болезнь сердца и дисфункцию эндотелия.</p></sec><sec><title>Цель</title><p>Цель. Рассмотреть основные ангиотензины и механизмы их действия на тонус сосудов, функционирование эндотелия, работу миокарда. Продемонстрировать участие ренин-ангиотензиновой системы в формировании основных видов патологии сердечно-сосудистой системы</p></sec><sec><title>Результаты</title><p>Результаты. В лекции рассмотрены кардиогенные и сосудистые эффекты ангиотензинов II, 1–7, 1–9 и роль этих ангиотензинов в развитии атеросклероза, ишемической болезни сердца, сердечной недостаточности, артериальной гипертензии. Приводятся основные принципы коррекции нарушения системы ангиотензинов и перспективные направления исследования этой проблемы.</p></sec><sec><title>Заключение</title><p>Заключение. Представление о классической ренин-ангиотензиновой системе, регулирующий артериальное давление и тонус сосудов, превратилось в понимание видения этой системы, как сложной сети медиаторов-антиотензинов и их рецепторов, влияющих на множество физиологических путей.</p><p>Хотя основные компоненты ренин-ангиотензиновой ситемы были открыты более полувека назад, эта система до сих пор привлекает большое количество исследовательских работ в различных областях. Ренин-ангиотензин-альдостероновая система обладает рядом регуляторных и контррегуляторных осей, оказывающих значимое влияние на течение многих заболеваний. Среди многочисленных вариантов сердечно-сосудистой терапии, используемых для лечения гипертонии и сердечной недостаточности, существенную терапевтическую роль играют препараты, влияющие на ренин-ангиотензин-альдостероновую систему.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. One of the main causes of death according to the World Health Organization is cardiovascular diseases. It is well known that dysregulation and/or overexpression of elements of the renin-angiotensin system leads to many negative vascular effects, thereby contributing to the development of cardiovascular diseases and pathological processes, including hypertension, aneurysms, congestive heart failure, stroke, coronary heart disease and endothelial dysfunction.</p></sec><sec><title>Aim</title><p>Aim. To consider the main angiotensins and the mechanisms of their action on vascular tone, endothelial functioning, and myocardial function. To demonstrate the participation of the renin-angiotensin system in the formation of the main types of cardiovascular pathology.</p></sec><sec><title>Results</title><p>Results. The lecture discusses the cardiogenic and vascular effects of angiotensins II, 1-7, 1-9 and the role of these angiotensins in the development of atherosclerosis, coronary heart disease, heart failure, and arterial hypertension. The article presents the main principles of correction of the angiotensin system disorder and promising directions of research of this problem.</p></sec><sec><title>Conclusion</title><p>Conclusion. The concept of the classical renin-angiotensin system regulating arterial pressure and vascular tone has evolved into the understanding of this system as a complex network of mediators-anti-tensins and their receptors affecting many physiological pathways.</p><p>Although the main components of the renin-angiotensin system were discovered more than half a century ago, this system still attracts a large number of researches works in various fields. The renin-angiotensin-aldosterone system has a number of regulatory and counter-regulatory axes that have a significant impact on the course of many diseases. Among the numerous options for cardiovascular therapy used to treat hypertension and heart failure, drugs that affect the renin-angiotensin-aldosterone system play a significant therapeutic role.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>локальная ренин-ангиотензиновая система</kwd><kwd>ангиотензин II</kwd><kwd>АТ(ангиотензин)1-рецептор</kwd><kwd>АТ(ангиотензин)2-рецептор</kwd><kwd>ангиотензин (1–7)</kwd><kwd>MasR</kwd><kwd>ангиотензин (1–9)</kwd></kwd-group><kwd-group xml:lang="en"><kwd>local renin-angiotensin system</kwd><kwd>angiotensin II</kwd><kwd>AT (angiotensin) 1-receptor</kwd><kwd>AT (angiotensin) 2-receptor</kwd><kwd>angiotensin (1–7)</kwd><kwd>MasR</kwd><kwd>angiotensin (1–9)</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization: global website. Available at: https://www.who.int/ru [accessed: 17.06.2024].</mixed-citation><mixed-citation xml:lang="en">World Health Organization: global website. Available at: https://www.who.int/ru [accessed: 17.06.2024].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization: global website. Cardiovascular diseases. Available at: https://www.who.int/ru/health-topics/cardiovascular-diseases#tab=tab_1 [accessed: 17.06.2024].</mixed-citation><mixed-citation xml:lang="en">World Health Organization: global website. Cardiovascular diseases. Available at: https://www.who.int/ru/health-topics/cardiovascular-diseases#tab=tab_1 [accessed: 17.06.2024].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Capric V., Priyan Chandrakumar H., Celenza-Salvatore J.N., Makaryus A. The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications [Internet]. Renin-Angiotensin Aldosterone System. IntechOpen; 2021. Available from: DOI:10.5772/intechopen.96415</mixed-citation><mixed-citation xml:lang="en">Capric V., Priyan Chandrakumar H., Celenza-Salvatore J.N., Makaryus A. The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications [Internet]. Renin-Angiotensin Aldosterone System. IntechOpen; 2021. Available from: DOI:10.5772/intechopen.96415</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803. DOI:10.1152/physrev.00036.2005</mixed-citation><mixed-citation xml:lang="en">Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803. DOI:10.1152/physrev.00036.2005</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad S., Ferrario C.M. Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018). Expert Opin Ther Pat. 2018;28(11):755-764. DOI:10.1080/13543776.2018.1531848</mixed-citation><mixed-citation xml:lang="en">Ahmad S., Ferrario C.M. Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018). Expert Opin Ther Pat. 2018;28(11):755-764. DOI:10.1080/13543776.2018.1531848</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Froogh G., Pinto J.T., Le Y. et al. Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol. 2017;312(2):H223-H231. DOI:10.1152/ajpheart.00534.2016</mixed-citation><mixed-citation xml:lang="en">Froogh G., Pinto J.T., Le Y. et al. Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol. 2017;312(2):H223-H231. DOI:10.1152/ajpheart.00534.2016</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sun Y., Weber K.T. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. J Lab Clin Med. 1996;127(1):94-101. DOI:10.1016/s0022-2143(96)90170-5</mixed-citation><mixed-citation xml:lang="en">Sun Y., Weber K.T. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. J Lab Clin Med. 1996;127(1):94-101. DOI:10.1016/s0022-2143(96)90170-5</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Martyniak A., Tomasik P.J. A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2022;13(1):16. DOI:10.3390/diagnostics13010016</mixed-citation><mixed-citation xml:lang="en">Martyniak A., Tomasik P.J. A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2022;13(1):16. DOI:10.3390/diagnostics13010016</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Paz Ocaranza M., Riquelme J.A., García L. et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116-129. DOI:10.1038/s41569-019-0244-8</mixed-citation><mixed-citation xml:lang="en">Paz Ocaranza M., Riquelme J.A., García L. et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116-129. DOI:10.1038/s41569-019-0244-8</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Turner A.J., Nalivaeva N.N. Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation. Peptides. 2022;151:170766. DOI:10.1016/j.peptides.2022.170766</mixed-citation><mixed-citation xml:lang="en">Turner A.J., Nalivaeva N.N. Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation. Peptides. 2022;151:170766. DOI:10.1016/j.peptides.2022.170766</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hilgers K.F., Kuczera M., Wilhelm M.J. et al. Angiotensin formation in the isolated rat hindlimb. J Hypertens. 1989;7(10):789-798. DOI:10.1097/00004872-198910000-00004</mixed-citation><mixed-citation xml:lang="en">Hilgers K.F., Kuczera M., Wilhelm M.J. et al. Angiotensin formation in the isolated rat hindlimb. J Hypertens. 1989;7(10):789-798. DOI:10.1097/00004872-198910000-00004</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kaschina E., Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70-88. DOI:10.1080/08037050310001057</mixed-citation><mixed-citation xml:lang="en">Kaschina E., Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70-88. DOI:10.1080/08037050310001057</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hrenak J., Paulis L., Simko F. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology. Int J Mol Sci. 2016;17(7):1098. DOI:10.3390/ijms17071098</mixed-citation><mixed-citation xml:lang="en">Hrenak J., Paulis L., Simko F. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology. Int J Mol Sci. 2016;17(7):1098. DOI:10.3390/ijms17071098</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">van Thiel B.S., van der Pluijm I., te Riet L. et al. The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 2015;763(Pt A):3-14. DOI:10.1016/j.ejphar.2015.03.090</mixed-citation><mixed-citation xml:lang="en">van Thiel B.S., van der Pluijm I., te Riet L. et al. The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 2015;763(Pt A):3-14. DOI:10.1016/j.ejphar.2015.03.090</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Le NA. Lipoprotein-associated oxidative stress: a new twist to the postprandial hypothesis. Int J Mol Sci. 2014;16(1):401-19. DOI:10.3390/ijms16010401</mixed-citation><mixed-citation xml:lang="en">Le NA. Lipoprotein-associated oxidative stress: a new twist to the postprandial hypothesis. Int J Mol Sci. 2014;16(1):401-19. DOI:10.3390/ijms16010401</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Romero J.C., Reckelhoff J.F. Role of Angiotensin and Oxidative Stress in Essential Hypertension. Hypertension. 1999;34(4):943-949. DOI:10.1161/01.HYP.34.4.943</mixed-citation><mixed-citation xml:lang="en">Romero J.C., Reckelhoff J.F. Role of Angiotensin and Oxidative Stress in Essential Hypertension. Hypertension. 1999;34(4):943-949. DOI:10.1161/01.HYP.34.4.943</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fang C., Schmaier A.H. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems. Pharmacol Res. 2020;160:105096. DOI:10.1016/j.phrs.2020.105096</mixed-citation><mixed-citation xml:lang="en">Fang C., Schmaier A.H. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems. Pharmacol Res. 2020;160:105096. DOI:10.1016/j.phrs.2020.105096</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Paz Ocaranza M., Riquelme J.A., García L. et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116-129. DOI:10.1038/s41569-019-0244-8</mixed-citation><mixed-citation xml:lang="en">Paz Ocaranza M., Riquelme J.A., García L. et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116-129. DOI:10.1038/s41569-019-0244-8</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Flores-Monroy J., Lezama-Martínez D., Martínez-Aguilar L. Function of renin angiotensin system on heart failure. Journal of Integrative Cardiology. 2016;2(5):380-386. DOI:10.15761/JIC.1000180</mixed-citation><mixed-citation xml:lang="en">Flores-Monroy J., Lezama-Martínez D., Martínez-Aguilar L. Function of renin angiotensin system on heart failure. Journal of Integrative Cardiology. 2016;2(5):380-386. DOI:10.15761/JIC.1000180</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zhong J., Basu R., Guo D. et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717-728. DOI:10.1161/CIRCULATIONAHA.110.955369.</mixed-citation><mixed-citation xml:lang="en">Zhong J., Basu R., Guo D. et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717-728. DOI:10.1161/CIRCULATIONAHA.110.955369.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kibel A, editor. Selected Chapters from the Renin-Angiotensin System [Internet]. IntechOpen; 2020. Available from: http://dx.doi.org/10.5772/intechopen.77666</mixed-citation><mixed-citation xml:lang="en">Kibel A, editor. Selected Chapters from the Renin-Angiotensin System [Internet]. IntechOpen; 2020. Available from: http://dx.doi.org/10.5772/intechopen.77666</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Харкевич Д.А. Фармакология. М.:ГЭОТАР-Медиа; 2021. [Kharkevich D.A. Pharmacology. M.:GEOTAR-Media; 2021 (In Russian)].</mixed-citation><mixed-citation xml:lang="en">Харкевич Д.А. Фармакология. М.:ГЭОТАР-Медиа; 2021. [Kharkevich D.A. Pharmacology. M.:GEOTAR-Media; 2021 (In Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz-López E.O., Ye D., Wu C. et. Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease. Hypertension. 2022;79(10):2115-2126. DOI:10.1161/HYPERTENSIONAHA.122.18731</mixed-citation><mixed-citation xml:lang="en">Cruz-López E.O., Ye D., Wu C. et. Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease. Hypertension. 2022;79(10):2115-2126. DOI:10.1161/HYPERTENSIONAHA.122.18731</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Pantzaris N.D., Karanikolas E., Tsiotsios K., Velissaris D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J Clin Med. 2017;6(6):61. DOI:10.3390/jcm6060061</mixed-citation><mixed-citation xml:lang="en">Pantzaris N.D., Karanikolas E., Tsiotsios K., Velissaris D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J Clin Med. 2017;6(6):61. DOI:10.3390/jcm6060061</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
